CMS allows reimbursement for Spectrum cancer drug Zevalin

11/4/2009 | Reuters

The CMS approved reimbursement for Spectrum Pharmaceuticals' non-Hodgkin's lymphoma drug Zevalin, effective Jan. 1. The ruling removes "a significant historical barrier" to use of the drug, CEO Rajesh Shrotriya said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI